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Center for International Blood and Marrow Transplant ResearchTransplantation-relatedmortality (TRM) is high afterHLA-mismatched umbilical cord blood (UCB) transplan-
tation (UCBT). In utero, exposure to noninherited maternal antigen (NIMA) is recognized by the fetus, which
induces Tregulator cells to that haplotype. It is plausible that UCBTs inwhich recipients arematched to donor
NIMAsmay alleviate some of the excessmortality associatedwith this treatment. To explore this concept, we
used marginal matched-pair Cox regression analysis to compare outcomes in 48 NIMA-matched UCBTs (ie,
theNIMAof the donorUCB unitmatched to the patient) and in 116 non–NIMA-matchedUCBTs. All patients
had a hematologic malignancy and received a single UCB unit. Cases and controls were matched on age, dis-
ease, disease status, transplantation-conditioning regimen, HLAmatch, and infused cell dose. TRMwas lower
after NIMA-matched UCBTs compared with NIMA-mismatched UCBTs (relative risk, 0.48; P5.05; 18% ver-
sus 32%at 5 years posttransplantation).Consequently, overall survivalwas higher afterNIMA-matchedUCBT.
The 5-year probability of overall survival was 55% after NIMA-matched UCBTs versus 38% after NIMA-
mismatchedUCBTs (P5.04).When facedwith the choice of multipleHLA-mismatchedUCBunits containing
adequate cell doses, selecting an NIMA-matched UCB unit may improve survival after mismatched UCBT.
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Umbilical cord blood (UCB) is an acceptable graft
choice when considering unrelated donor transplanta-
tion for patients with hematologic malignancies. UCB
grafts are used for approximately 20% of unrelated do-
nor transplantations for hematologic malignancies in
the United States and approximately 12% in Europe.
We and others have reported similar leukemia-free
survival despite higher transplantation-related mortal-
ity (TRM) after UCB transplantation (UCBT) com-
pared with transplantation of HLA-matched bone
marrow or peripheral blood progenitor cells from un-
related adult donors in children and adults with leuke-
mia [1,2].
High TRM after UCBT remains a significant lim-
itation and can be attributed to multiple factors. Some
of the excess TRM after UCBT results from infusion
of units containing relatively low total nucleated cell
(TNC) doses. The accepted standard now is to use
a UCB unit containing a minimum pre-
cryopreserved TNC of 3  107/kg patient body
weight, with some recommending an incremental in-
crease in TNC to overcome the HLA barrier [3,4].
When such a UCB unit is not available, the
coinfusion of 2 unmanipulated UCB units is used to
deliver higher TNC doses [4,5]. Infusion of
expanded hematopoietic progenitor cells with
a single UCB unit is also used to deliver higher
TNC doses [6,7]. Avoiding UCB units with donor-
specific anti-HLA antibodies present in the recipient
decreases the risk of graft failure and mortality
[8-10]. The importance of better donor–recipient
HLA matching for unrelated adult donor
transplantation is clear [11]. The best results are ob-
tained with an unrelated adult donor allele-matched
to the recipient at HLA-A, -B, -C, and -DRB1.Match-
ing the UCB unit to the recipient at the HLA-C locus
is associated with lower TRM [12]. The role of allelic
HLA matching at HLA-A, -B, and -C remains to be
determined in the setting of UCBT.
Two independent clinical studies conducted a de-
cade apart [13,14] found tolerance to noninherited
maternal antigens (NIMAs) in renal transplant
recipients, implying that fetal exposure to NIMAs
may promote lasting tolerance in humans. As the
fetal immune system develops, T cells develop
tolerance to self-antigens and recognize and react
against foreign antigens. The placental circulation
permits the crossing of maternal cells to the fetus
and vice versa. Mold et al. [15] recently reported that
the human fetal immune system generates regulatory
T cells (CD41CD25highFoxP31 Tregs) that suppress
fetal immune responses to maternal antigens, and
that this tolerance persists at least until early adult-
hood. In a recent study reported by the New York
Blood Center, HLA-mismatched UCBTs in whichthe mismatched antigen in the recipient matched the
NIMA of the UCB donor (NIMA-matched transplan-
tation) were associated with greater neutrophil recov-
ery and lower mortality [16]. However, in another
recent report from the same group, NIMA-matched
UCBTs were not associated with TRM or overall
mortality, even though both analyses were performed
on largely the same cohort of donor–recipient pairs
[17]. Given that the majority of UCBTs are mis-
matched andTRMpresents a barrier to successful out-
come, the present analysis was undertaken in an
independent cohort of patients to determine whether
matching the recipient to the UCB unit’s noninherited
maternal antigen (ie, NIMA) [16] would indeed de-
crease the mortality associated with mismatched
UCBT.METHODS
Data Collection
This study included patients reported to
Eurocord-European Group for Blood and Marrow
Transplantation and the Center for International
Blood and Marrow Transplant Research. Eligibility
criteria included available data on UCB unit HLA typ-
ing, UCB donor maternal HLA typing, or maternal
sample and recipient HLA typing. Seven Netcord
banks in Europe and 10 cord blood banks in the U.S.
National Marrow Donor Program (NMDP) network
provided the UCB units. Data for UCBTs in Europe
were obtained from Eurocord, and data for UCBTs
in the United States were obtained from the Center
for International Blood and Marrow Transplant Re-
search. All patients received a single unrelated UCB
unit for treatment of leukemia, lymphoma, or myelo-
dysplastic syndrome. Patients who received UCB units
matched at HLA-A, -B, and -DRB1, coinfusion of 2
units, or expanded units were excluded. All patients
(or their guardians) provided written consent for re-
search. The Institutional Review Boards of the Medi-
cal College of Wisconsin, the Eurocord-Netcord
Scientific Committee, and the NMDP approved this
study.
HLATyping and Match Assignment
Donor, donor maternal, and recipient HLA typing
were considered matching at HLA-A, -B, and -DRB1.
Donor–recipient match grades were assigned consid-
ering HLA-A and -B at intermediate resolution (anti-
gen level) and HLA-DRB1 at high resolution (allele
level). For UCBTs facilitated by the Netcord banks,
maternal HLA typing data were available from the
banks. For UCBTs facilitated by theNMDP,maternal
HLA typing was obtained from the banks when avail-
able, or HLA typing of banked maternal samples was
Table 1. Examples of NIMA Matching and NIMA Mismatch-
ing in the Setting of a Single LocusMismatchedUmbilical Cord
Blood Transplant
HLA-A HLA-B HLA-DRB1
NIMA matched*
UCB unit/donor A*02, 32 B*18, 35 DRB1*01:01, 11:04
UCB donor mother A*24, 32 B*07, 35 DRB1*01:01, 13:01
Recipient A*02, 24 B*18, 35 DRB1*01:01, 11:04
NIMA mismatched†
UCB unit/donor A*02, 32 B*18, 35 DRB1*01:01, 11:04
UCB donor mother A*24, 32 B*07, 35 DRB1*01:01, 13:01
Recipient A*01, 02 B*18, 35 DRB1*01:01, 11:04
*HLA-A*24 is not carried by UCB donor. HLA-A*24 is carried by the
UCB donor’s mother and the recipient; thus, this is an NIMA-matched
UCBT.
†HLA-A*01 is not carried by UCB donor or the UCB donor’s mother;
thus, this is an NIMA-mismatched UCBT.
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based methods. Maternal HLA typing was scored at
intermediate resolution (antigen level) for HLA-A
and -B and at high resolution (allele level) for HLA-
DRB1. UCBTs were classified as NIMA-matched or
NIMA-mismatched based on review of recipient, do-
nor, and donor maternal HLA typing at HLA-A, -B,
and -DRB1. In an NIMA-matched UCBT, the mis-
matched antigen of the recipient was matched to the
noninherited maternal antigen of the UCB donor. In
contrast, in NIMA-mismatched UCBT, the mis-
matched antigen of the recipient was not matched to
the noninherited maternal antigen of the UCB donor.
Examples of NIMA-matched and NIMA-mismatched
UCBTs are provided in Table 1.
Outcomes
TRMwas defined as the time from transplantation
to death not related to disease recurrence or progres-
sion. Overall mortality was defined as death from any
cause. Neutrophil recovery was defined as achieving
an absolute neutrophil count $0.5  109/L for 3 con-
secutive measurements on different days. Grade II-IV
acute [18] and chronic [19] graft-versus-host disease
(GVHD) was based on reports using standard criteria
from each transplantation center. Disease recurrence
was based on morphological evaluation, supported by
the reappearance of abnormalities in cytogenetic or
molecular analyses.
Statistical Methods
The probabilities of TRM, recurrent disease, neu-
trophil recovery, and acute and chronic GVHD were
calculated using the cumulative incidence estimator
to accommodate competing risks [20]. The probability
of overall survival was calculated using the Kaplan-
Meier estimator [20]; 95% confidence intervals (CIs)
were calculated with log-transformation.
To assess the association between clinical out-
comes and NIMA matching, cases (NIMA matched)
were matched to controls (NIMA mismatched). A
matched-pair analysis was considered appropriate
given the relatively low frequency of NIMA-matched
transplantations (8.5%). Before matching cases to con-
trols, we built a multivariate Cox regression model for
TRM using patients who met the study eligibility cri-
teria (n 5 508) [21]. Results are expressed as relative
risk (RR). The characteristics of this cohort are
presented in Supplemental Table 1. Fifty-two
donor–recipient pairs were NIMA-matched, and 456
donor–recipient pairs were NIMA-mismatched. We
aimed to identify variables other than NIMAmatching
with a significant effect on TRM: patient age, donor–
recipient HLAmatch, disease status at transplantation,
and transplantation conditioning regimen were signif-
icantly associated with TRM (Supplemental Table 2).Cases were matched to controls for patient age, HLA
match, disease status, conditioning regimen, and 2
other variables (disease type and total nucleated cell
dose [TNC]#3 107/kg versus.3 107/kg), known
to be frequently associated with UCBT outcomes.
The final study population included 48 NIMA-
matched and 116NIMA-mismatched transplant recip-
ients. Nineteen cases were matched to 76 controls
(1:4), 1 case was matched to 3 controls (1:3), 9 cases
were matched to 18 controls (1:2), and 19 cases were
matched to 19 controls (1:1). To assess the association
between clinical outcomes andNIMAmatching status,
using matched pairs, we built marginal Cox regression
models for neutrophil recovery, acute and chronic
GVHD, TRM, disease recurrence, and overall mortal-
ity [21]. Models were built with the forward stepwise
selection procedure and confirmed with the use of
the backward selection procedure. All variables met
the proportional hazards assumption. All P values are
2-sided, with values of #.05 considered statistically
significant. All analyses were performed using SAS
9.2 (SAS Institute, Cary, NC).
The frequencies of NIMA-matched and NIMA-
mismatched antigens in U.S. transplantations were
evaluated by comparing the average antigen (HLA-A
and -B) and allele (HLA-DRB1) frequencies within
the overall population. HLA frequencies for the U.S.
donor population provided by the NMDP were
used as a reference. NIMA-matched and NIMA-
mismatched antigens/alleles were aggregated by locus,
and average frequency was compared between the
NIMA-matched and -mismatched groups using
2-sided t tests. Analyses were performed for the overall
population and the Caucasian subset.RESULTS
Patient, Disease, and Transplant Characteristics
Characteristics of cases and controls are shown in
Table 2. Some 75% of patients were age 16 years or
Table 2. Patient, Disease, and Transplant Characteristics of
the Study Population
Variable
NIMA-
Mismatched
UCBT, n (%)
NIMA-
Matched
UCBT, n (%)
Number 116 48
Region
Europe 37 (32) 27 (56)
United States 79 (68) 21 (44)
Age
#16 years 91 (78) 30 (62)
>16 years 25 (22) 18 (38)
Disease
Acute myelogenous leukemia 48 (41) 21 (44)
Acute lymphoblastic leukemia 47 (41) 18 (38)
Chronic myelogenous leukemia 1 (1) 1 (2)
Myelodysplastic syndrome 10 (9) 4 (8)
Other acute leukemias 8 (7) 3 (6)
Non-Hodgkin lymphoma 2 (2) 1 (2)
Disease status
First complete remission/
chronic phase
31 (27) 12 (25)
Second complete remission/
chronic phase/accelerated phase
56 (48) 22 (46)
Relapse, refractory anemia with
excess blasts
29 (25) 14 (29)
Conditioning regimen
Myeloablative
Total body irradiation–containing 58 (50) 19 (40)
Non–irradiation-containing 43 (37) 15 (31)
Reduced intensity
Total body irradiation–containing 13 (11) 10 (20)
Non–irradiation-containing 2 (1) 4 (8)
Infused total nucleated cell dose
#3  107/kg recipient body weight 25 (22) 16 (33)
>3  107/kg recipient body weight 91 (78) 32 (67)
GVHD prophylaxis
Cyclosporine alone or with steroids 56 (48) 23 (48)
Cyclosporine + methotrexate 12 (10) 5 (10)
Cyclosporine + mycophenolate mofetil 31 (27) 14 (29)
Tacrolimus + methotrexate 7 (6) 3 (6)
Tacrolimus + mycophenolate mofetil 5 (4) 1 (2)
Tacrolimus alone 5 (4) 2 (4)
Donor–recipient HLA match
5/6 HLA match 43 (36) 14 (27)
4/6 HLA match 73 (63) 34 (71)
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and 46% were cytomegalovirus-seropositive. Acute
leukemia was the most common indication for trans-
plantation, and 74% of transplantations occurred in
remission. A total body irradiation–containing mye-
loablative conditioning regimen was used in 82% of
transplantations, and cyclosporine alone or in combi-
nation with steroids, methotrexate, or mycophenolate
mofetil for GVHD prophylaxis was used in 86%.
Thirty-five percent of transplantations were mis-
matched at 1 HLA locus, and the remainder were
matched at 2 HLA loci. All UCBTs were performed
between 2002 and 2009; 50% of the NIMA-matched
and 42% of NIMA-mismatched transplantations
were performed between 2002 and 2005, and the re-
mainder were done between 2006 and 2009. Three-
quarters of recipients received .3  107/kg TNCs.
The median follow-up of surviving patients was
42 months (range, 3-103 months) after NIMA-matched UCBT and 36 months (range, 3-93 months)
after NIMA-mismatched UCBT.
Neutrophil Recovery
Neutrophil recovery was similar after NIMA-
matched and NIMA-mismatched transplantations
(relative risk [RR], 1.18; 95% CI, 0.80-1.74;
P5 .42). The median time to recovery was 20 days af-
ter transplantation of NIMA-matched UCB units and
23 days after transplantation of NIMA-mismatched
units. The corresponding day 28 probabilities of re-
covery were 71% (95% CI, 57%-81%) and 59%
(95% CI, 50%-67%).
Acute and Chronic GVHD
Risks of grade II-IV acute GVHD (RR, 0.94; 95%
CI, 0.56-1.59; P5 .82) and chronic GVHD (RR, 0.85;
95% CI, 0.44-1.63; P 5 .61) were not different after
NIMA-matched and NIMA-mismatched transplanta-
tions. The day 100 probabilities of grade II-IV acute
GVHD were 40% (95% CI, 26%-53%) after
NIMA-matched transplantations and 46% (95% CI,
37%-54%) after NIMA-mismatched transplantations.
The corresponding 5-year probabilities of chronic
GVHD were 26% (95% CI, 15%-39%) and 27%
(95% CI, 19%- 35%).
TRM and Overall Mortality
The risk of TRM was lower after NIMA-matched
UCBT compared with NIMA-mismatched UCBT
(RR, 0.48; 95% CI, 0.23-1.01; P 5 .05) (Figure 1A).
Similarly, overall mortality risk was also lower after
NIMA-matched UCBT (RR, 0.61; 95% CI, 0.38-
0.98; P 5 .04) (Figure 1B). Data on infections that
occurred in the first 100 days after transplantation
were available for 113 of 164 (69%) transplants. The
day 30 cumulative incidence of infections was 15% af-
ter NIMA-matched UCBT and 27% after NIMA-
mismatched USBT (P 5 .24). The corresponding
day 100 cumulative incidence rates were 48% and
50%. Six of 20 deaths (30%) after NIMA-matched
UCBT were attributed to TRM. Four of these 6
deaths occurred within 6 months after transplantation
(2 due to multiorgan failure, 1 due to infection, and 1
due to hemorrhage). Two deaths occurred beyond
6 months (1 from infection and the other from chronic
GVHD). Thirty-one of 66 deaths (47%) after NIMA-
mismatched transplantations were attributed to TRM.
Twenty-three of the 31 deaths occurred within 6
months of transplantation, with 6 due to multiorgan
failure, 8 due to infection, 4 due to adult respiratory
distress syndrome/interstitial pneumonitis, 2 due to
diffuse alveolar hemorrhage, and 1 due to Epstein-
Barr virus posttransplantation lymphoproliferative
disease; cause of death was not reported for 2 patients.
Eight deaths occurred beyond 6 months, including
Figure 1. (A) The 5-year probabilities of transplant-related mortality
were 18% (95% CI, 8%-29%) after NIMA-matched transplantation and
32% (95% CI, 23%-41%) after NIMA-mismatched transplantation. (B)
The 5-year probabilities of overall survival were 55% (95% CI,
40%-69%) after NIMA-matched transplantation and 38% (95% CI,
29%-48%) after NIMA-mismatched transplantation.
1894 Biol Blood Marrow Transplant 18:1890-1896, 2012V. Rocha et al.2 due to chronic GVHD, 3 due to infection, and 2 due
to multiorgan failure; cause of death was not reported
for 1 patient.
Relapse
The relapse risk was similar after NIMA-matched
and NIMA-mismatched UCBTs (RR, 0.82; 95% CI,
0.47-1.43; P5 .47). The 5-year probabilities of relapse
were 31% (95% CI, 18%-44%) after NIMA-matched
transplantations and 33% (95% CI, 24%-42%) after
NIMA-mismatched transplantations.
Influence of Antigen Frequency on NIMA
Matching
The frequencies of NIMA-matched and NIMA-
mismatched antigens/alleles were evaluated for the
U.S. cohort (n 5 429). Transplantations in Europe
were excluded because information on the race of
UCB and recipients was not always available. The anti-
gen (HLA-A and -B) and allele (HLA-DRB1) frequen-
cies recorded in theNMDPdonor registry served as the
reference values for the study population and were ad-
justed based on subject race. Overall, NIMA-matched
antigens/alleles had higher population-based frequen-
cies than NIMA-mismatched antigens/alleles (0.110
versus 0.052;P\.001).TheNIMAmatcheswere all as-
sociated with relatively common HLA antigens (fre-
quencies .0.058), whereas the NIMA-mismatched
antigenswere observed across commonanduncommonHLAantigens.Themost frequentNIMAmatch (n5 6;
22%)was atHLA-A*02,which is also themost common
antigen in the U.S. Caucasian population, with a fre-
quency of 0.308 [22]. To ensure that HLA-A*02 was
not inordinately influencing these results, we repeated
the analysis and restricted the population to non–
HLA-A*02mismatches. Consistent with themain anal-
ysis, the frequency of non–HLA-A*02 NIMA-matched
antigens was higher than that of NIMA-mismatched
antigens (0.107 versus 0.054; P5 .008).DISCUSSION
The primary objective of the present study was to
assess the effect of tolerance to NIMA and its effect
on mortality after HLA-mismatched UCBT. Al-
though tolerance to NIMA in renal transplantation is
well documented [13,14], tolerance to NIMA and its
effect on survival after mismatched UCBT is by no
means conclusive [16,17]. To circumvent the
problems related to the relatively small sample of
NIMA-matched transplantations, we used
a matched-pair analysis, matching recipients for fac-
tors that influence TRM and overall survival, which al-
lowed us to carefully control the analysis.We observed
marginally lower TRM and overall mortality after
NIMA-matched UCBT compared with NIMA-
mismatched UCBT, consistent with the earlier report
on the impact of NIMAs in UCBT [16]. We hypothe-
size that allowing for permissive mismatching between
UCB units and recipient reduced some of the excess
mortality associated with HLA-mismatched UCBT.
The exact mechanism by which mortality is reduced
is not easily explained, however. The higher survival
afterNIMA-matchedUCBTwas likely related tomul-
tiple factors, including better hematopoietic recovery,
lower rates of acute GVHD and infections in the early
posttransplantation period, and better immune recon-
stitution, which together contributed to the observed
survival advantage.
In contrast to studies of haploidentical transplanta-
tions [23], we failed to see significant differences in
rates of acute or chronic GVHD after NIMA-
matched and NIMA-mismatched UCBTs. Rates of
acute and chronic GVHD after UCBT are substan-
tially lower than after haploidentical transplantations.
Given that only 10% of mismatched UCBTs are
NIMA-matched, studies involving hundreds of pa-
tients are needed to definitively identify differences
in GVHD rates after NIMA-matched and NIMA-
mismatched transplantations.
Better HLA matching of donors and recipients is
associated with better hematopoietic recovery and
thus lower early mortality. In this analysis, we found
a 12%difference in the probability of neutrophil recov-
ery after NIMA-matched and NIMA-mismatched
transplantations. Our inability to detect a statistically
Biol Blood Marrow Transplant 18:1890-1896, 2012 1895Effect of Matching at NIMA and UCB Transplantationsignificant difference can be explained by the small
sample size and the ensuing wide confidence intervals
of probability estimates. Furthermore, the use of
UCB units with relatively high TNC (.3  107/kg)
also might have diminished the importance of NIMA
matching for neutrophil recovery, as has been shown
to be the case with HLA-mismatched UCBTs [3,24].
Consistent with our findings, studies of tolerance to
NIMAs after haploidentical transplantations in which
very high cell doses were used also have failed to
show an association between NIMA matching and
neutrophil recovery [23,25]. Of note, most deaths
from transplantation-related complications occurred
within 6 months after transplantation. There may be
differences in immune reconstitution after NIMA-
matched and NIMA-mismatched transplantations,
but we cannot test this hypothesis in our study popula-
tion. We used data reported to transplantation regis-
tries, in which information on immune reconstitution
was not available.
NIMA-matched transplants account for less than
10% of UCBTs. Incorporating NIMA matching in an
algorithm for UCB unit selection is complex and logis-
tically challenging. Given that maternal HLA typing
data are not available for banked UCB units, NIMA-
matched transplantation is more likely to occur ran-
domly than by choice. However, approximately
one-third of the cord banks in Netcord/NMDP rou-
tinely perform UCB unit maternal HLA typing, and
the availability of maternal and UCB unit HLA typing
data will allow physicians select UCB units that are
NIMA matched to the recipient. Furthermore, based
on our observations of the HLA types within the U.S.
study cohort, NIMA matching is correlated with the
frequency of mismatched antigens in the U.S. popula-
tion. Therefore, searching for an NIMA-matched
UCB unit is best facilitated by selecting a mismatched
UCB unit in which the mismatch is a high-frequency
HLA-antigen within the target population, such as
HLA-A*02 in Caucasians [21]. However, truly under-
standing the probability of finding an NIMA match
within a given population will require either complex
mathematical models based on HLA haplotype fre-
quencies or the addition of maternal HLA typing to
UCB unit registries. Consultation with an HLA expert
during the searchmay allow aphysician to apply the sur-
rogate approach described here to identify a potential
NIMA-matched UCB unit and request donor maternal
HLA typing at the time of confirmatory HLA typing of
theUCBunit.The additional request formaternalHLA
typing by those banks that donot routinely performma-
ternal HLA typing will add to their financial burden.
Taken together, our current analysis and the ear-
lier report [16] suggest that the use of UCB units in
which the recipient is matched to the donor NIMA
may ameliorate some of the excess mortality associated
with HLA-mismatched UCBT. Both studies are lim-ited by modest numbers of NIMA-matched transplan-
tations, however. Although we performed a carefully
controlled analysis that considered risk factors associ-
ated with higher mortality risk, several unknown and
unmeasured factors also might have influenced sur-
vival after UCBT. Nevertheless, the marginal survival
advantage associated with NIMA-matched transplan-
tation cannot be ignored. Thus, when considering
mismatched UCBT for hematologic malignancy, ef-
forts to obtain donor maternal HLA typing from
cord blood banks should be encouraged. Matching re-
cipients to donor NIMA must be considered along
with other known factors associated with lowering
mortality risks.ACKNOWLEDGMENTS
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